USA - engelsk - NLM (National Library of Medicine)

ligand pharmaceuticals incorporated - alitretinoin (unii: 1ua8e65kdz) (alitretinoin - unii:1ua8e65kdz) - gel - 1 mg in 1 g - panretin® gel is indicated for topical treatment of cutaneous lesions in patients with aids-related kaposi’s sarcoma. panretin® gel is not indicated when systemic anti-ks therapy is required (e.g., more than 10 new ks lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary ks, or symptomatic visceral involvement). there is no experience to date using panretin® gel with systemic anti-ks treatment. panretin® gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

2care4 aps - alitretinoin - kapsel, mjuk - 10 mg - sorbitol hjälpämne; sojaolja, partiellt hydrogenerad hjälpämne; sojaolja, raffinerad hjälpämne; alitretinoin 10 mg aktiv substans; glycerol hjälpämne

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

2care4 aps - alitretinoin - kapsel, mjuk - 30 mg - sojaolja, partiellt hydrogenerad hjälpämne; sorbitol hjälpämne; sojaolja, raffinerad hjälpämne; glycerol hjälpämne; alitretinoin 30 mg aktiv substans

Østerrike - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

glaxosmithkline pharma gmbh - alitretinoin - alitretinoin

Østerrike - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

glaxosmithkline pharma gmbh - alitretinoin - alitretinoin

Den europeiske union - slovensk - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastična sredstva - panretin gel je navedena za lokalno zdravljenje kožne lezije pri bolnikih s pridobljenim-imunski-pomanjkljivosti-sindrom (aids), povezanih z kaposi ' s sarkom (ks), če:so poškodbe, ki niso ulcerated ali lymphoedematous, in;zdravljenje globokih ks, ni potrebno, in;poškodbe se ne odziva na sistemski antiretrovirusne terapije, in;naprave za radioterapijo ali kemoterapijo niso primerne.

Den europeiske union - latvisk - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarkoma, kapoši - antineoplastiski līdzekļi - panretin želeja ir norādīts lokālai ārstēšanai, ādas bojājumi pacientiem ar iegūto-imūnsistēmas vājums-sindroms (aids)-saistīti ar kapoši sarkoma (ks), ja:bojājumi nav ulcerated vai lymphoedematous, un;ārstēšana viscerālo ks nav nepieciešams, un;bojājumi, kas nereaģē uz sistēmisko antiretrovirālā terapija un staru terapijas vai ķīmijterapijas nav piemērota.

Den europeiske union - slovakisk - EMA (European Medicines Agency)

eisai gmbh - alitretinoín - sarkóm, kaposi - antineoplastické činidlá - panretin gél je indikovaný na lokálne ošetrenie kožných lézií u pacientov s nadobudlo imunitnej nedostatočnosti-syndróm (aids) súvisiace s kaposiho sarkóm (ks), ak:lézie nie sú ulcerated alebo lymphoedematous, a;liečbu viscerálneho ks nie je potrebné, a;lézie sú nereaguje na systémové antiretrovírusovej liečby, a;prístroje na rádioterapiu alebo chemoterapiu nie sú vhodné.

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - alitretinoin - קפסולות רכות - alitretinoin 10 mg - alitretinoin - alitretinoin - for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids .patients in whom the eczema has predominantly hyperkeratotic features are more likely to respond to treatment than in those in whom the eczema predominantly presents as pompholyx .

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - alitretinoin - קפסולות רכות - alitretinoin 30 mg - alitretinoin - alitretinoin - for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids .patients in whom the eczema has predominantly hyperkeratotic features are more likely to respond to treatment than in those in whom the eczema predominantly presents as pompholyx .